GLP-1 Spillover, AI Empowerment... Could Biopharmaceuticals Become the 'Alternative' to Tech Stocks in 2026?

Citi noted that the indications for GLP-1 are expanding from weight management to cardiovascular and nervous system applications, alongside an anticipated expansion of Medicare coverage and the launch of Eli Lilly and Co’s oral medication orforglipron; AI is fully delivering cost and efficiency gains across R&D, production, and clinical stages; in addition, the DTP (Direct-to-Patient) model is reshaping distribution channels. As a result, the industry’s overall profitability and innovation conversion efficiency are significantly improving.

wallstreetcnJan 7 16:43

Following a significant personnel change at the US FDA, shares of multiple biopharmaceutical companies surged, with Replimune's stock skyrocketing by over 75%.

①Vinay Prasad, a senior official at the U.S. Food and Drug Administration (FDA), has left the agency after nearly three months as the Director of the Center for Biologics Evaluation and Research (CBER); ②Prasad had been a vocal critic of Sarepta's Elevidys, a treatment for Duchenne muscular dystrophy. His departure is seen as a bullish sign for gene therapy and vaccine companies.

cls.cnJul 30, 2025 22:23

Wall Street Set to Open Higher Friday Ahead of Consumer Sentiment, Home Sales Data

MT NewswiresJan 19, 2024 22:14

U.S. Shares Higher at Close of Trade; Dow Jones Industrial Average up 0.54%

InvestingJan 19, 2024 05:30

12 Health Care Stocks Moving In Thursday's Pre-Market Session

BenzingaJan 18, 2024 21:05

Changes in US stocks 丨 Aravive plummeted more than 57% before the market and will be delisted from NASDAQ

GLONGHUI, January 18 | Oncology company Aravive plummeted more than 57% to $0.046 before the market. Earlier, the company announced that it would voluntarily delist from the NASDAQ Global Select Market and deregister its common stock. The NASDAQ delisting is expected to take effect around February 8.

Gelonghui FinanceJan 18, 2024 17:27